Roth MKM Reiterates Buy on Immix Biopharma, Maintains $14 Price Target
Immix Biopharma Analyst Ratings
Roth MKM Keeps Their Buy Rating on Immix Biopharma, Inc. (IMMX)
Immix Biopharma Analyst Ratings
Roth MKM Initiates Coverage On Immix Biopharma With Buy Rating, Announces Price Target of $14
No Data